Ignite Creation Date:
2025-12-24 @ 4:58 PM
Ignite Modification Date:
2026-01-28 @ 11:01 PM
Study NCT ID:
NCT00005950
Status:
TERMINATED
Last Update Posted:
2013-01-23
First Post:
2000-07-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Angioimmunoblastic T-cell Lymphoma | View |
| None | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | View |
| None | Nodal Marginal Zone B-cell Lymphoma | View |
| None | Recurrent Adult T-cell Leukemia/Lymphoma | View |
| None | Recurrent Grade 1 Follicular Lymphoma | View |
| None | Recurrent Grade 2 Follicular Lymphoma | View |
| None | Recurrent Marginal Zone Lymphoma | View |
| None | Recurrent Small Lymphocytic Lymphoma | View |
| None | Splenic Marginal Zone Lymphoma | View |
| None | Waldenström Macroglobulinemia | View |
Keywords: